title: Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care VII--Guidelines for antibiotic administration in severely injured patients.
abstract: When the clinical decision to treat a critically ill patient with antibiotics has been made, one must attempt to identify the site of infection based on clinical signs and symptoms, laboratory or diagnostic radiology studies. Identification of site requires, examination of patient, inspection of all wounds, chest radiograph, and calculation of clinical pulmonary infection score if ventilated, obtaining blood cultures, urinalysis, and line change if clinical suspicion of central venous catheter (CVC) source. If it is impossible to identify site, obtain cultures from all accessible suspected sites and initiate empiric, broad spectrum antibiotics. If likely site can be identified answer these questions: Is intra-abdominal site suspected? Is pulmonary source of infection suspected? Is skin, skin structure or soft tissue site suspected? If yes, does the patient have clinical signs suspicion for necrotizing soft tissue infection (NSTI)? Is a CVC infection suspected? Risk factors for more complicated infections are discussed and specific antibiotic recommendations are provided for each type and severity of clinical infection. Decision to continue, discontinue and/or alter antibiotic/antimicrobial treatment should be based on the clinical response to treatment, diagnostic or interventional findings, and culture and sensitivity data, bearing in mind that not all patients with infections will have positive cultures because of limitations of specimen handling, microbiology laboratory variations, time between specimen acquisition and culture, or presence of effective antibiotics at the time that specimens were obtained. It should also be noted that not all patients with increased temperature/WBC have an infection. Discontinuation of antibiotics is appropriate if cultures and other diagnostic studies are negative.
authors.affiliation: Department of Surgery, University of California, San Francisco, San Francisco, California 94110, USA. michael.west@ucsf.edu
authors.forename: Michael A
authors.initials: MA
authors.lastname: West
authors.forename: Ernest E
authors.initials: EE
authors.lastname: Moore
authors.forename: Michael B
authors.initials: MB
authors.lastname: Shapiro
authors.forename: Avery B
authors.initials: AB
authors.lastname: Nathens
authors.forename: Joseph
authors.initials: J
authors.lastname: Cuschieri
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Johnson
authors.forename: Brian G
authors.initials: BG
authors.lastname: Harbrecht
authors.forename: Joseph P
authors.initials: JP
authors.lastname: Minei
authors.forename: Paul E
authors.initials: PE
authors.lastname: Bankey
authors.forename: Ronald V
authors.initials: RV
authors.lastname: Maier
mesh_terms: D000465:Algorithms; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D001431:Bacteriological Techniques; D003428:Cross Infection / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D003661:Decision Support Techniques; D024901:Drug Resistance, Multiple, Bacterial; D019317:Evidence-Based Medicine; D006801:Humans; D007362:Intensive Care Units; D008826:Microbial Sensitivity Tests; D009104:Multiple Trauma / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000601:surgery; D018805:Sepsis / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents